255 related articles for article (PubMed ID: 9733519)
21. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy.
Dong DL; Chen C; Huo R; Wang N; Li Z; Tu YJ; Hu JT; Chu X; Huang W; Yang BF
Hypertension; 2010 Apr; 55(4):946-52. PubMed ID: 20177001
[TBL] [Abstract][Full Text] [Related]
22. Ablation of the N terminus of cardiac essential light chain promotes the super-relaxed state of myosin and counteracts hypercontractility in hypertrophic cardiomyopathy mutant mice.
Sitbon YH; Kazmierczak K; Liang J; Yadav S; Veerasammy M; Kanashiro-Takeuchi RM; Szczesna-Cordary D
FEBS J; 2020 Sep; 287(18):3989-4004. PubMed ID: 32034976
[TBL] [Abstract][Full Text] [Related]
23. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy.
Redwood CS; Moolman-Smook JC; Watkins H
Cardiovasc Res; 1999 Oct; 44(1):20-36. PubMed ID: 10615387
[TBL] [Abstract][Full Text] [Related]
24. Differential activation of stress-response signaling in load-induced cardiac hypertrophy and failure.
Rothermel BA; Berenji K; Tannous P; Kutschke W; Dey A; Nolan B; Yoo KD; Demetroulis E; Gimbel M; Cabuay B; Karimi M; Hill JA
Physiol Genomics; 2005 Sep; 23(1):18-27. PubMed ID: 16033866
[TBL] [Abstract][Full Text] [Related]
25. Calcineurin inhibitor attenuates cardiac hypertrophy due to energy metabolic disorder.
Kamiya H; Okumura K; Ito M; Saburi Y; Tomida T; Hayashi K; Matsui H; Hayakawa T
Can J Cardiol; 2001 Dec; 17(12):1292-8. PubMed ID: 11773940
[TBL] [Abstract][Full Text] [Related]
26. Pathogenesis of dilated cardiomyopathy: molecular, structural, and population analyses in tropomodulin-overexpressing transgenic mice.
Sussman MA; Welch S; Gude N; Khoury PR; Daniels SR; Kirkpatrick D; Walsh RA; Price RL; Lim HW; Molkentin JD
Am J Pathol; 1999 Dec; 155(6):2101-13. PubMed ID: 10595939
[TBL] [Abstract][Full Text] [Related]
27. Tropisetron inhibits high glucose-induced calcineurin/NFAT hypertrophic pathway in H9c2 myocardial cells.
Asadi F; Razmi A; Dehpour AR; Shafiei M
J Pharm Pharmacol; 2016 Apr; 68(4):485-93. PubMed ID: 26945895
[TBL] [Abstract][Full Text] [Related]
28. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy.
McMullen JR; Amirahmadi F; Woodcock EA; Schinke-Braun M; Bouwman RD; Hewitt KA; Mollica JP; Zhang L; Zhang Y; Shioi T; Buerger A; Izumo S; Jay PY; Jennings GL
Proc Natl Acad Sci U S A; 2007 Jan; 104(2):612-7. PubMed ID: 17202264
[TBL] [Abstract][Full Text] [Related]
29. Calcineurin in human heart hypertrophy.
Ritter O; Hack S; Schuh K; Röthlein N; Perrot A; Osterziel KJ; Schulte HD; Neyses L
Circulation; 2002 May; 105(19):2265-9. PubMed ID: 12010908
[TBL] [Abstract][Full Text] [Related]
30. Cyclosporin A regulates sodium-calcium exchanger (NCX1) gene expression in vitro and cardiac hypertrophy in NCX1 transgenic mice.
Jordan MC; Quednau BD; Roos KP; Ross RS; Philipson KD; Nicholas SB
Ann N Y Acad Sci; 2002 Nov; 976():259-67. PubMed ID: 12502568
[TBL] [Abstract][Full Text] [Related]
31. Consequences of pressure overload on sarcomere protein mutation-induced hypertrophic cardiomyopathy.
Schmitt JP; Semsarian C; Arad M; Gannon J; Ahmad F; Duffy C; Lee RT; Seidman CE; Seidman JG
Circulation; 2003 Sep; 108(9):1133-8. PubMed ID: 12925456
[TBL] [Abstract][Full Text] [Related]
32. Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function.
Sommese RF; Sung J; Nag S; Sutton S; Deacon JC; Choe E; Leinwand LA; Ruppel K; Spudich JA
Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12607-12. PubMed ID: 23798412
[TBL] [Abstract][Full Text] [Related]
33. Hereditary heart disease: pathophysiology, clinical presentation, and animal models of HCM, RCM, and DCM associated with mutations in cardiac myosin light chains.
Yadav S; Sitbon YH; Kazmierczak K; Szczesna-Cordary D
Pflugers Arch; 2019 May; 471(5):683-699. PubMed ID: 30706179
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin II induced cardiac hypertrophy in vivo is inhibited by cyclosporin A in adult rats.
Goldspink PH; McKinney RD; Kimball VA; Geenen DL; Buttrick PM
Mol Cell Biochem; 2001 Oct; 226(1-2):83-8. PubMed ID: 11768242
[TBL] [Abstract][Full Text] [Related]
35. Enhanced Ca2+ channel currents in cardiac hypertrophy induced by activation of calcineurin-dependent pathway.
Yatani A; Honda R; Tymitz KM; Lalli MJ; Molkentin JD
J Mol Cell Cardiol; 2001 Feb; 33(2):249-59. PubMed ID: 11162130
[TBL] [Abstract][Full Text] [Related]
36. An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy.
Fatkin D; McConnell BK; Mudd JO; Semsarian C; Moskowitz IG; Schoen FJ; Giewat M; Seidman CE; Seidman JG
J Clin Invest; 2000 Dec; 106(11):1351-9. PubMed ID: 11104788
[TBL] [Abstract][Full Text] [Related]
37. Mechanical stress-evoked but angiotensin II-independent activation of angiotensin II type 1 receptor induces cardiac hypertrophy through calcineurin pathway.
Zhou N; Li L; Wu J; Gong H; Niu Y; Sun A; Ge J; Zou Y
Biochem Biophys Res Commun; 2010 Jun; 397(2):263-9. PubMed ID: 20580688
[TBL] [Abstract][Full Text] [Related]
38. Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress.
Frey N; Barrientos T; Shelton JM; Frank D; Rütten H; Gehring D; Kuhn C; Lutz M; Rothermel B; Bassel-Duby R; Richardson JA; Katus HA; Hill JA; Olson EN
Nat Med; 2004 Dec; 10(12):1336-43. PubMed ID: 15543153
[TBL] [Abstract][Full Text] [Related]
39. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
[TBL] [Abstract][Full Text] [Related]
40. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo.
Passier R; Zeng H; Frey N; Naya FJ; Nicol RL; McKinsey TA; Overbeek P; Richardson JA; Grant SR; Olson EN
J Clin Invest; 2000 May; 105(10):1395-406. PubMed ID: 10811847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
